Pfizer-BioNTech data lift global faith in Covid-19 vaccines, but set 'extremely high bar' for competitors
After data from early studies came out, scientists were cautiously optimistic that the first Covid-19 vaccines would prove effective, but they had no idea how effective. Given their experience with other respiratory virus vaccines, they cautioned it wouldn’t be a “magic wand.” The FDA set the bar at only 50%.
Now, the first batch of data from a Phase III trial is in, and, according to Pfizer, it shows the inoculation can reduce the risk of contracting a symptomatic case of Covid-19 by more than 90%. The results floored experts, including NIAID chief Anthony Fauci, but one company can’t vaccinate the world. What does it mean for the rest of the candidates in mid and late-stage trials?
Keep reading Endpoints with a free subscription
Unlock this story instantly and join 98,600+ biopharma pros reading Endpoints daily — and it's free.